Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Dna X (SONM) EPS (Weighted Average and Diluted) (2022 - 2025)

Dna X filings provide 4 years of EPS (Weighted Average and Diluted) readings, the most recent being $8.14 for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 109.94% to $8.14 in Q4 2025 year-over-year; TTM through Dec 2025 was $2.6, a 102.79% increase, with the full-year FY2025 number at -$11.0, up 91.43% from a year prior.
  • EPS (Weighted Average and Diluted) hit $8.14 in Q4 2025 for Dna X, up from -$4.83 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $8.14 in Q4 2025 to a low of -$81.87 in Q4 2024.
  • Median EPS (Weighted Average and Diluted) over the past 4 years was -$0.26 (2023), compared with a mean of -$5.71.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): surged 400.0% in 2023 and later tumbled 26309.68% in 2024.
  • Dna X's EPS (Weighted Average and Diluted) stood at $0.03 in 2022, then crashed by 1133.33% to -$0.31 in 2023, then tumbled by 26309.68% to -$81.87 in 2024, then soared by 109.94% to $8.14 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were $8.14 (Q4 2025), -$4.83 (Q3 2025), and -$0.79 (Q2 2025) per Business Quant data.